Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

被引：0
|
作者：
Yumi Asukai
Amparo Valladares
Carlos Camps
Eifiona Wood
Kaisa Taipale
Jorge Arellano
Alejo Cassinello
José Antonio Sacristán
Tatiana Dilla
机构：
[1] IMS Health,
[2] Eli Lilly SA,undefined
[3] Hospital General Universitario,undefined
[4] Eli Lilly,undefined
[5] Erl Wood Manor,undefined
来源：
BMC Cancer | / 10卷
关键词：
Docetaxel; Erlotinib; Pemetrexed; Malignant Pleural Mesothelioma; Good Supportive Care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
    Asukai, Yumi
    Valladares, Amparo
    Camps, Carlos
    Wood, Eifiona
    Taipale, Kaisa
    Arellano, Jorge
    Cassinello, Alejo
    Antonio Sacristan, Jose
    Dilla, Tatiana
    [J]. BMC CANCER, 2010, 10
  • [2] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    [J]. PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [3] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    [J]. PharmacoEconomics, 2004, 22 : 581 - 589
  • [4] Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
    Shi, Yafei
    Chen, Wei
    Zhang, Yujun
    Bo, Mingming
    Li, Chunyu
    Zhang, Mingyu
    Li, Guohui
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
  • [5] Pemetrexed vs docetaxel cost analysis in second-line non-small cell lung cancer treatment
    Ravasio, Roberto
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (02) : 119 - 126
  • [6] A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China
    Yu, Yong-feng
    Chen, Zhi-wei
    Zhou, Zhen
    Song, Zheng-bo
    Li, Zi-ming
    Jian, Hong
    Zhang, Yi-fei
    Lu, Shun
    [J]. CHEMOTHERAPY, 2010, 56 (06) : 472 - 477
  • [7] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL, PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN RUSSIA
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
  • [8] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
  • [9] Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
    Gonzalez, P.
    Ortega-Joaquin, N.
    Provencio Pulla, M.
    Garrido, C.
    Echave, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
12345